Google
Trusted Resources: News & Events
Latest announcements and gatherings
SPCI Launched the SCOT (Sickle Cell Omega-3 Treatment) Trial in the United States with an Investigator Meeting Held December 16-17 in Atlanta
Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the start of the first of two placebo controlled clinical trials in US pediatric patients affected with Sickle Cell Disease (SCD). Recruitment in the trial is underway and enrollment is expected to be completed by Q2 2017 and will be immediately followed by a second placebo controlled clinical study in Q3 2017.
SCD is estimated to affect 100,000 Americans, with a disproportional impact on African Americans.
“It has taken us nearly 3 years to get to the point of dosing children in the United States who have this horrible disease. I am excited by the data we’ve seen in studies performed abroad, but having only children from the United States in such a study will be exciting and conclusive,” said Dr. Frederick Sancilio, CEO of SPCI.
+myBinderRelated Content
-
Maternal/Perinatal Outcome in Women With Sickle Cell Disease: A Comparison of Two Time PeriodsObjective: To compare pregnancy outcome...
-
La Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
-
Piracetam for reducing the incidence of painful sickle cell disease crisesBACKGROUND: Sickle cell disease is one ...
-
SCDAA News Advisory: Partial Hold on Gene Therapy TrialOn December 20, the FDA placed a partial...
-
Mount Sinai receives NIH grant to study use of inhaled corticosteroids for sickle cell treatmentThe Departments of Emergency Medicine an...
-
Statement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
-
LentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data ReportsBluebird bio presented new positive resu...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.